Trial Profile
Rosuvastatin effects on CD4+CD28null T-cells in patients with troponin-positive acute coronary syndromes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2011
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Acute coronary syndromes
- Focus Pharmacodynamics
- 01 Feb 2011 Results published in Clinical Research in Cardiology.
- 05 Nov 2010 New trial record.